Company intelligence / Profile preview

Let's Disco

Cologne, North Rhine-Westphalia, Germanyebay.com ↗

Ownership: Private
Development stage: Other

Overview

Disco Pharmaceuticals has developed a proprietary platform for comprehensive mapping of the cancer cell "surfaceome" to identify novel druggable targets. The company has completed the first-ever full map of small cell lung cancer's surfaceome and initiated preclinical development of antibody-based therapies targeting these newly discovered proteins. Early results have validated their approach and enabled rapid expansion into additional tumor types such as microsatellite-stable colorectal cancer. No clinical trial data are available yet.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Partnerships

AbbVie VenturesSofinnova PartnersPanakes PartnersM Ventures

Beyond the preview

Go deeper on Let's Disco.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Let's Disco.

Explore the full profile